Navigation Links
Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
Date:3/6/2008

Majority of DVT Cases Treated in Single-Setting With Trellis-8 Catheter

From Bacchus Vascular, Reducing Patient Lytic Exposure, Bleeding

Complications and Treatment Cost

SANTA CLARA, Calif., March 6 /PRNewswire/ -- Bacchus Vascular Inc., a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and interventional cardiologists for the minimally invasive treatment of deep vein thrombosis (DVT) and other peripheral vascular disease, announced today that the Journal of Vascular Interventional Radiology (JVIR) has published a study comparing the clinical use of the Trellis-8 infusion catheter from Bacchus Vascular with conventional catheter-directed thrombolysis (CDT) in the treatment of DVT in its March 2008 issue.

Results of the study showed that Grade II and III lysis was achieved in 93% of patients treated with the Trellis catheter and 79% of patients treated with CDT even though thrombolytic doses and infusion durations were less with the Trellis catheter than with conventional CDT. Major hemorrhage was reported in none of the Trellis catheter patients and in 8.5% of patients treated with CDT. The per-patient cost of therapy was $3,697 for the Trellis catheter and $5,473 for CDT. This cost reduction is due to approximately 80% of the Trellis catheter patients being treated in the single-setting of the interventional suite with less time required for follow-up monitoring in a costly critical care unit compared with CDT patients.

The study, which was authored by Daniel E. Hilleman, PharmD (Department of Pharmacy Practice, Creighton University School of Pharmacy, Omaha, NE) and Mahmood K. Razavi, MD (Department of Vascular and Interventional Radiology, Stanford University Hospital, Stanford, CA), compared retrospectively collected data from 147 patients treated for DVT with the Trellis-8 infusion catheter at 45 hospitals in the U.S. and three hospitals outside the U
'/>"/>

SOURCE Bacchus Vascular Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
2. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
3. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
6. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
7. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
8. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
9. AMTs Lead Product Poised to Address Major Liver Disease
10. SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
11. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... , Purpose ... several different metabolite identification approaches are evaluated for their merits. A ... performed to illustrate data quality and types of metabolites found. A ... to create a thorough investigation of the metabolites derived from glyburide. ...
... , This application note describes ... software for Phase I and Phase II metabolite identification and discusses its ... Overview , ... more emphasis on characterization of potential drug candidates earlier in the discovery ...
... Specifications , Accelerating Your Research with the BD ... , . , ... new BD High Throughput Sampler (HTS) provides fully automated and rapid sample acquisition. ... sample carryover tolerances of 1% or less. The BD HTS adapts to ...
Cached Biology Technology:Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 2Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 3Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 4Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 5Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System 6Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 2Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 3Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 4Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System 5Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 2Technical Specifications, Accelerating Your Research with the BD FACSCanto, High Throughput Sampler Option 3
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... tracking of threatened loggerhead sea turtles has revealed two previously ... providing important habitat for at least three separate populations of ... journal Biological Conservation . The two sites, ... Florida and the northern tip of the Yucatan Peninsula, were ...
... Case Western Reserve University are joining forces to ... will investigate and develop better protection and treatment ... to sports, military service and automobile accidents. ... have collaborated on state-of-the-art research in collision sports. ...
... -- Think of it as cooking with carbon spaghetti: ... to create and work with carbon nanotubes -- ultrasmall ... These carbon nanotubes -- made of graphene, an ... for improving laser detectors and rechargeable batteries, according to ...
Cached Biology News:Satellite tracking reveals sea turtle feeding hotspots 2Satellite tracking reveals sea turtle feeding hotspots 3Cleveland Clinic, Case Western Reserve University form research consortium 2Cleveland Clinic, Case Western Reserve University form research consortium 3The right recipe: Engineering research improves laser detectors, batteries 2The right recipe: Engineering research improves laser detectors, batteries 3
... does for enzyme-/substrate-based blotting what intensifying screens do ... up to 10-fold (or one order of magnitude) ... Signal Enhancer membrane treatment is a simple, 15-minute ... current Western blotting protocol. The result is an ...
...
... Expression is a revolutionary new ... analysis. Utilising a novel interface, Expression ... information incredibly simple. Expression uses the ... new standards in the way sequences ...
... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
Biology Products: